tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Amylyx Pharmaceuticals Inc (AMLX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Capricor Therapeutics (CAPRResearch Report) and Amylyx Pharmaceuticals Inc (AMLXResearch Report) with bullish sentiments.

Capricor Therapeutics (CAPR)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics, with a price target of $18.00. The company’s shares closed last Tuesday at $3.73.

According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -27.9% and a 21.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Bioline RX Ltd Sponsored ADR, and Lineage Cell Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Capricor Therapeutics with a $15.00 average price target, a 317.8% upside from current levels. In a report issued on June 28, Maxim Group also assigned a Buy rating to the stock with a $12.00 price target.

See the top stocks recommended by analysts >>

Amylyx Pharmaceuticals Inc (AMLX)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $35.00. The company’s shares closed last Tuesday at $19.50.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.0% and a 33.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Global Blood Therapeutics, and Deciphera Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amylyx Pharmaceuticals Inc with a $33.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CAPR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed